Granulomatosis with Polyangiitis (GPA) Market to Reach USD 595.2 Million by 2034

Pune, India - December 2025 - The global Granulomatosis with Polyangiitis (GPA) Market, valued at USD 344.7 million in 2024, is projected to reach USD 595.2 million by 2034, growing at a 5.4% CAGR (2025-2034), according to Exactitude Consultancy. Rising autoimmune disease detection, greater utilization of ANCA testing, and advancements in biologic therapies are contributing to market expansion.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72286

Market Summary
The Granulomatosis with Polyangiitis Market is growing steadily as diagnostic and therapeutic capabilities improve for this rare autoimmune vasculitis characterized by inflammation of small-to-medium blood vessels. GPA-formerly known as Wegener's granulomatosis-primarily affects the kidneys, respiratory tract, ENT system, and can cause life-threatening organ damage if untreated. Increased availability of ANCA (anti-neutrophil cytoplasmic antibody) testing, improved clinical awareness, and access to advanced imaging tools (CT, MRI, PET) are expanding the diagnosed patient pool globally.

Treatment paradigms have shifted significantly with the adoption of rituximab, glucocorticoids, immunosuppressants (cyclophosphamide, methotrexate, azathioprine), and emerging biologic therapies targeting autoimmune pathways. Advances in maintenance therapy, relapse prevention, and steroid-sparing regimens are improving patient outcomes. North America and Europe currently lead in documented prevalence due to strong rheumatology networks, while Asia-Pacific is the fastest-growing region, driven by improved diagnostic infrastructure and rising autoimmune disease awareness.

Key Takeaways
• 2024 Market Size: USD 344.7 Million
• 2034 Forecast: USD 595.2 Million
• CAGR: 5.4% (2025-2034)
• ANCA testing and imaging improvements increasing early detection
• Rituximab remains a cornerstone therapy for induction and maintenance
• Asia-Pacific witnessing rapid growth due to rising autoimmune awareness

Market Drivers
• Growing prevalence of autoimmune vasculitis disorders
• Increased adoption of ANCA diagnostics and advanced imaging techniques
• Expanding availability of biologic and immunosuppressive treatments
• Improvements in long-term disease monitoring and relapse management
• Expansion of rheumatology care networks and specialty clinics

Segmentation Snapshot
By Disease Type
• Localized GPA
• Systemic GPA
• Severe Organ-Involving GPA

By Treatment
• Glucocorticoids
• Immunosuppressive Therapies (Cyclophosphamide, Methotrexate, Azathioprine)
• Biologics (Rituximab, Emerging Agents)
• Plasma Exchange (in severe cases)
• Supportive & Symptomatic Treatment

By Diagnosis Method
• ANCA Testing (c-ANCA, p-ANCA)
• Kidney & Tissue Biopsy
• Imaging (CT, MRI, PET)
• Urinalysis & Renal Function Tests
• ENT Examination

By End User
• Hospitals
• Specialty Rheumatology Centers
• Diagnostic Laboratories
• Research Institutes

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/72286/granulomatosis-with-polyangiitis-market

Recent Developments
• Increased use of rituximab as a first-line therapy for both induction and maintenance.
• Research into next-generation biologics targeting autoimmune inflammation.
• Enhanced ANCA testing accuracy through automated immunoassay platforms.
• Growing use of PET imaging for vasculitis monitoring and treatment response assessment.

Expert Quote - Irfan Tamboli, Business Development Executive
"Improved diagnostics and biologic therapies are transforming the management of granulomatosis with polyangiitis. Earlier detection and better relapse-prevention strategies are significantly improving patient survival and quality of life."

Conclusion
The Granulomatosis with Polyangiitis Market will continue expanding through 2034 as adoption of immunosuppressive and biologic therapies increases, diagnostics improve, and specialty rheumatology infrastructures grow globally. Companies investing in ANCA testing, biologic R&D, and autoimmune disease management solutions will lead the next wave of market innovation.

This report is also available in the following languages : Japanese (多発血管炎性肉芽腫症市場), Korean (다발혈관염을 동반한 과립종증 시장), Chinese (肉芽肿性多血管炎市场), French (Marché de la granulomatose avec polyangéite), German (Markt für Granulomatose mit Polyangiitis), and Italian (Granulomatosi con poliangioite Mercato), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/72286

Related Reports

High Purity Mullite Powder Market
https://exactitudeconsultancy.com/reports/75174/high-purity-mullite-powder-market

High Purity PFA Resins Market
https://exactitudeconsultancy.com/reports/75212/high-purity-pfa-resins-market

Crystalline Fructose Market
https://exactitudeconsultancy.com/reports/75364/crystalline-fructose-market

Sulfur Guard Catalyst Sales Market
https://exactitudeconsultancy.com/reports/75701/sulfur-guard-catalyst-sales-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.